Inhibrx Biosciences, Inc. (INBX)vsRevolution Medicines Inc (RVMD)
INBX
Inhibrx Biosciences, Inc.
$127.58
-5.04%
HEALTHCARE · Cap: $1.86B
RVMD
Revolution Medicines Inc
$144.15
+1.65%
HEALTHCARE · Cap: $30.65B
Smart Verdict
WallStSmart Research — data-driven comparison
Inhibrx Biosciences, Inc. generates 75% more annual revenue ($1.30M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs 0.0%. RVMD earns a higher WallStSmart Score of 24/100 (F).
INBX
Avoid20
out of 100
Grade: F
RVMD
Avoid24
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
Safe zone — low bankruptcy risk
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 232.0x book value
Trading at 17.4x book value
0.0% earnings growth
0.0% margin — thin
Operating margin of 0.0%
Comparative Analysis Report
WallStSmart ResearchBull Case : INBX
INBX has a balanced fundamental profile.
Bull Case : RVMD
The strongest argument for RVMD centers on Altman Z-Score.
Bear Case : INBX
The primary concerns for INBX are EPS Growth, Market Cap, Profit Margin.
Bear Case : RVMD
The primary concerns for RVMD are Price/Book, EPS Growth, Profit Margin.
Key Dynamics to Monitor
RVMD is growing revenue faster at -95.2% — sustainability is the question.
INBX generates stronger free cash flow (-30M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
RVMD scores higher overall (24/100 vs 20/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Inhibrx Biosciences, Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates. The company is headquartered in La Jolla, California.
Revolution Medicines Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?